Apixaban reduces the risk of major and clinically relevant non-major bleeding compared to warfarin in patients with end stage renal disease; a systematic review and meta-analysis of ten studies

Optimal anticoagulation in patients with end-stage renal disease ESRD is a matter of debate since these patients are not included in randomized controlled trials (RCTs). Evolving data are in favor of apixaban compared to warfarin.

Source: Thrombosis Research - September 20, 2023 Category: Hematology Authors: Konstantinos Zagoridis, Lazaros Karatisidis, Theodoros Mprotsis, Aikaterini Pentidou, Zoi Bezirgianidou, Christina Misidou, Emmanouil Spanoudakis Tags: Full Length Article Source Type: research